Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9BU40
UPID:
CRDL1_HUMAN
Alternative names:
Neuralin-1; Neurogenesin-1; Ventroptin
Alternative UPACC:
Q9BU40; B1AKD0; B4DMP3; D3DUY6; E9PGS5; Q539E4; Q9Y3H7
Background:
Chordin-like protein 1, known by its aliases Neuralin-1, Neurogenesin-1, and Ventroptin, plays a pivotal role in neural stem cell fate determination, promoting neurogenesis over gliogenesis. It antagonizes BMP4, preventing its interaction with receptors, crucial for dorsoventral axis formation and embryonic bone development. Additionally, it regulates retinal angiogenesis and is instrumental in anterior segment eye development.
Therapeutic significance:
Given its involvement in Megalocornea 1, X-linked, a disorder characterized by enlarged corneal diameter and potential complications like cataract and glaucoma, Chordin-like protein 1 presents a target for therapeutic intervention. Understanding its role could open doors to potential therapeutic strategies.